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Cyclic GMP (cGMP) is synthesized by renal proximal
tubule (RPT) cells and is exported from these cells into the
renal interstitial (RI) compartment by an organic anion
transporter system. We have demonstrated that RI gGMP
inhibits renal Na+ reabsorption at the renal tubule. We
have further demonstrated that cGMP-induced natriuresis
can be blocked by intrarenal pharmacological inhibition
of protein kinase G (PKG). In order to demonstrate that RI
cGMP is a potent physiological regulator of Na+ excretion,
we selectively decreased RI cGMP using an RI infusion of
cGMP-specific phosphodiesterase (PDE), which does not
cross the cell membrane and is confined to the extracellu-
lar space because of its molecular size. cGMP PDE selec-
tively decreased extracellular RI cGMP levels, without
influencing cAMP levels, and caused significant anti-
natriuresis. On the other hand, blockade of cGMP degra-
dation with selective cGMP PDE inhibitor, zaprinast,
increased both RI cGMP and sodium excretion, independ-
ently of systemic or renal hemodynamic changes. There-
fore, extracellular RI cGMP plays an important role in the
regulation of renal Na+ excretion.
Pressure-natriuresis (P-N) is the major regulatory mecha-
nism in mammalian physiology whereby an elevation in
blood pressure (BP) induces a rapid increase in renal Na+
excretion. P-N normally protects the organism from a
long-term rise in BP by reducing extracellular fluid vol-
ume. Virtually all forms of hypertension in experimental
animals and humans are accompanied by a defective
natriuretic response to increased BP. Thus, in the hyper-
tensive state a normal rate of Na+ excretion is achieved
only at the expense of increased BP. In an experimental rat
P-N model, we demonstrated that increasing renal per-
fusion pressure (RPP) rapidly releases cGMP into the RI
space. The RPP-induced increase in RI cGMP was accom-
panied by natriuresis due to inhibition of RPT Na+ reab-
sorption as indicated by increased in fractional Na+ and
Li+ excretion and no change in glomerular filtration rate
(GFR). When cGMP export from the tubule cell was
blocked by administration of organic anion transport
inhibitor probenecid, the pressure-induced icrements in
both RI cGMP and Na+ excretion were eliminated. P-N as
well as the increase in RI cGMP were also blocked by intra-
renal inhibition of cGMP formation using guanylyl
cyclase inhibitor ODQ (1-H-[1,2,4]oxadiazolo[4,2-α]qui-
noxalin-1-one). P-N also was blocked by intrarenal
administration of PKG inhibitor Rp-8-pCTP-cGMPs.
These results strongly suggest that P-N is mediated by RI
cGMP.
Studies in human RPT cells confirmed the antinatriuretic
action of cGMP in vivo. We employed the Na+-sensitive
indicator Na-Green to measure changes in intracellular
Na+ in response to NO donor SNAP (S-nitroso-N-
acetylpenicillamine), cGMP and 8-Br-cGMP. RPT cells
were studied in the presence of ouabain, an inhibitor of
Na+/K+ ATPase. SNAP (10-4M) significantly decreased
intracellular Na+ and probenecid this response to SNAP.
Extracellular cGMP, which did not enter the cell, reduced
intracellular Na+. These results indicate that RPT cells con-
tain soluble guanylyl cyclase and are able to synthesize
cGMP in response to NO. These observations also
strongly suggest that export of cGMP from the cell is
required to inhibit apical Na+ transport.
Taken altogether, the results indicate that natriuresis and
P-N are mediated physiologically by RIcGMP.
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